Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Mol Oncol. 2015 Sep 15;10(1):138–147. doi: 10.1016/j.molonc.2015.09.002

Figure 2. HER2 selected reaction monitoring-mass spectrometry (SRM-MS) results for 277 breast cancers previously classified as IHC negative (0+, 1+), equivocal (2+) or positive (3+) with subsequent ISH central retesting results. SRM-MS-positive = HER2 protein >740 amol/μg. Discordant cases are highlighted. −, negative; +, positive; na, not assessed.

Figure 2